Towards a targeted, risk-based, antifungal strategy in neutropenic patients.
about
Galactomannan detection for invasive aspergillosis in immunocompromized patientsMicafungin: an evidence-based review of its place in therapyT2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasisEpidemiology of invasive candidiasis: a persistent public health problemContribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan.MALDI-TOF mass spectrometry proteomic phenotyping of clinically relevant fungi.Prophylactic antifungal therapy in the intensive care unit.Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?Impaired gut function as risk factor for invasive candidiasis in neutropenic patients.High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan.Antifungal agent utilization evaluation in hospitalized neutropenic cancer patients at a large teaching hospital.Advances in the molecular and serological diagnosis of invasive fungal infection in haemato-oncology patients.Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide.Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.Fungal infections in bone marrow transplant recipients.Invasive fungal infections in acute leukemia.Voriconazole is a safe and effective anti-fungal prophylactic agent during induction therapy of acute myeloid leukemia.Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.Significance of amplified fragment length polymorphism in identification and epidemiological examination of Candida species colonization in children undergoing allogeneic stem cell transplantation.Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China.Antifungal prophylaxis and treatment in patients with hematological malignancies.Immune response to Aspergillus fumigatus in compromised hosts: from bedside to bench.Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies.Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy.Survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant haematology and haemopoietic stem cell transplantation (HSCT) in Australia and New Zealand.Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014.Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis.The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.Invasive aspergillosis of the small bowel in an infant with acute myeloid leukemia and intestinal obstruction.Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy.Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin.Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field.Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia.Chest CT scans are frequently abnormal in asymptomatic patients with newly diagnosed acute myeloid leukemia.Evolution of procalcitonin, C-reactive protein and fibrinogen levels in neutropenic leukaemia patients with invasive pulmonary aspergillosis or mucormycosis.Prevention of Invasive Aspergillosis in High-Risk Patients: Universal Versus Preemptive, Targeted Treatment.Antifungal prophylaxis with micafungin in neutropenic patients with hematological malignancies.Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
P2860
Q24240734-BBEED6AB-CB27-489F-A295-085F65D15A08Q27014780-22E50FC5-C2CF-4720-8D61-19CDA45696B8Q28084998-252D332D-39CB-4380-B693-FA0C68FC41EAQ29616758-FBE8C472-FA06-463E-9C0B-FC8D4CCCF89FQ33592749-BF26717E-C3CD-41D5-8112-548E437E7600Q33725726-E9333C17-1611-4276-A71C-4522640C854FQ34205622-D9AA8220-6E4B-42F1-9820-CEC4125E9E46Q34490092-C5ADA675-38B8-4660-B16F-F9C1E39365B5Q34612183-751C253C-FC37-45FC-831E-EACCBA6B225FQ35659664-C8C31FFD-0E4F-4EB5-A336-595FA89179F6Q35687657-DFFDE46E-8569-4260-B7EA-C591333249AAQ35838440-24480D64-827B-4603-9A7C-E0A5B6397E83Q36028504-BFAF1A97-5D98-4D22-89F9-B8873EC4AAE0Q36349776-AC26F24E-4C64-450F-ADE8-81A6376A7FDAQ36382582-5CF74704-041F-422C-AD72-BA84E5422269Q36612597-BC04D1B6-3BE4-49FD-98A4-4E66545E86B3Q36696390-66996F4C-8654-46DD-9227-0631EA7398B9Q36714507-EB5301CB-AC92-49D5-BA3D-EFB05A848A1FQ37043539-71EBCB3E-AE1B-4FB4-A0D3-74213709F13BQ37419898-9DEEFD9A-D924-4B46-9B0B-2D19A75182CAQ37624076-829EED60-32D7-48CC-A683-8FB9EECA3EAAQ37727168-A3DF4EDD-7DF6-4B06-9A79-57F8AB8F041CQ37821488-EBB8B5DA-C769-404B-9519-C79DE61E8DD4Q37833638-C4F12632-CC05-4C65-B605-1329366BE6D1Q37900678-1F6444A8-08CF-41D3-AC16-62F5A330AEBBQ38284453-3B554B33-4621-45F8-AD3D-5872FA3D28C2Q38284455-A14F51E5-2394-47A6-B1D2-86EF6600FED9Q38589279-2816BEBD-253F-459F-AEC0-260C6F91B22EQ40255550-C72ED3EA-4FF4-4D1D-93D8-5CCEAC45A398Q40397551-42BAC798-15E1-4CBB-A9C3-23EA5DA92340Q40454115-AA9B5533-BB30-4BF1-B7E2-E11D3F0E165BQ40489288-F860CB44-EAAF-41FA-9135-74A724E4BD9AQ40497134-729AF92A-D4EC-465F-946D-59E9E827B8E2Q40515140-CC017FCA-AD6E-4EE2-AEB2-26E40F7492B6Q40517272-197BAA48-002B-4C91-9E5A-9BFB2078D082Q40535692-0CAB904F-8235-4FB4-A58B-C121343BB718Q40771604-02E9E5B0-2084-4C6F-BBA3-E89965641FA3Q41688288-B244B927-9A21-444D-BE57-9AEB337812F4Q43137240-091991C4-4F26-4F67-A718-CFC712310581Q46341880-CDC1B94F-13AF-4A1F-83FD-EAAFB5F461E8
P2860
Towards a targeted, risk-based, antifungal strategy in neutropenic patients.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Towards a targeted, risk-based, antifungal strategy in neutropenic patients.
@ast
Towards a targeted, risk-based, antifungal strategy in neutropenic patients.
@en
Towards a targeted, risk-based, antifungal strategy in neutropenic patients.
@nl
type
label
Towards a targeted, risk-based, antifungal strategy in neutropenic patients.
@ast
Towards a targeted, risk-based, antifungal strategy in neutropenic patients.
@en
Towards a targeted, risk-based, antifungal strategy in neutropenic patients.
@nl
prefLabel
Towards a targeted, risk-based, antifungal strategy in neutropenic patients.
@ast
Towards a targeted, risk-based, antifungal strategy in neutropenic patients.
@en
Towards a targeted, risk-based, antifungal strategy in neutropenic patients.
@nl
P2093
P2860
P1476
Towards a targeted, risk-based, antifungal strategy in neutropenic patients.
@en
P2093
Kibbler CC
Prentice AG
Prentice HG
P2860
P304
P356
10.1046/J.1365-2141.2000.02014.X
P407
P577
2000-08-01T00:00:00Z